Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of Aleph Inactivated Split Influenza Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* more than three years in good healthy~Exclusion Criteria:~* current infectious fever or acute disease~* upper respiratory infectious symptom within 6m~* a history of allergy~* laboratory confirmed influenza~* autoimmune disease~* have get influenza vaccine since 2008

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- recombinant hepatitis b vaccine (Type: PLACEBO_COMPARATOR): 0.5ml intramuscular
- Aleph influenza vaccine (Type: EXPERIMENTAL): 0.5ml intramuscular

Based on this trial design, predict the completion outcome and termination type (if applicable).